Multifunctional, CD44v6-Targeted ORMOSIL Nanoparticles Enhance Drugs Toxicity in Cancer Cells.
CD44 receptor
antibodies
hyaluronic acid
silica nanoparticles
targeted delivery
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
10 Feb 2020
10 Feb 2020
Historique:
received:
27
11
2019
revised:
24
01
2020
accepted:
31
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
14
2
2020
Statut:
epublish
Résumé
Drug-loaded, PEGylated, organic-modified silica (ORMOSIL) nanoparticles prepared by microemulsion condensation of vinyltriethoxysilane (VTES) were investigated as potential nanovectors for cancer therapy. To target cancer stem cells, anti-CD44v6 antibody and hyaluronic acid (HA) were conjugated to amine-functionalized PEGylated ORMOSIL nanoparticles through thiol-maleimide and amide coupling chemistries, respectively. Specific binding and uptake of conjugated nanoparticles were studied on cells overexpressing the CD44v6 receptor. Cytotoxicity was subsequently evaluated in the same cells after the uptake of the nanoparticles. Internalization of nanocarriers loaded with the anticancer drug 3N-cyclopropylmethyl-7-phenyl-pyrrolo- quinolinone (MG2477) into cells resulted in a substantial increase of the cytotoxicity with respect to the free formulation. Targeting with anti-CD44v6 antibodies or HA yielded nanoparticles with similar effectiveness, in their optimized formulation.
Identifiants
pubmed: 32050605
pii: nano10020298
doi: 10.3390/nano10020298
pmc: PMC7075197
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : MSCA-ITN-2016 MMBio 721613
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : FIRB 2011 RINAME RBAP114AMK
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biomed Pharmacother. 2017 Nov;95:856-864
pubmed: 28903181
Nanotechnology. 2009 Aug 26;20(34):345101
pubmed: 19652275
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
Arch Biochem Biophys. 1959 May;82(1):70-7
pubmed: 13650640
Nanomedicine (Lond). 2015;10(13):1993-5
pubmed: 26096565
Cancer Res. 2001 Mar 15;61(6):2592-601
pubmed: 11289136
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):279-84
pubmed: 15630089
Bioconjug Chem. 2008 Jun;19(6):1319-25
pubmed: 18481885
J Control Release. 2014 Dec 28;196:122-31
pubmed: 25305563
Nanomedicine (Lond). 2010 Aug;5(6):881-96
pubmed: 20735224
Br J Cancer. 2017 Jan 17;116(2):186-194
pubmed: 27931044
Stem Cells Transl Med. 2015 Sep;4(9):1033-43
pubmed: 26136504
J Am Chem Soc. 2003 Jul 2;125(26):7860-5
pubmed: 12823004
J Am Chem Soc. 2019 Nov 6;141(44):17670-17684
pubmed: 31604010
Matrix Biol. 2017 May;59:3-22
pubmed: 27746219
Int J Pharm. 2007 Feb 1;329(1-2):94-102
pubmed: 16997518
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
ACS Nano. 2017 Mar 28;11(3):2313-2381
pubmed: 28290206
Biochemistry. 1998 Jun 23;37(25):8965-72
pubmed: 9636038
Cell. 1991 Apr 5;65(1):13-24
pubmed: 1707342
Small. 2018 Feb;14(7):
pubmed: 29251426
Clin Cancer Res. 2009 Dec 15;15(24):7462-7468
pubmed: 20008845
Histopathology. 2005 Oct;47(4):420-8
pubmed: 16178897
Nanomedicine. 2015 Feb;11(2):313-27
pubmed: 25461284
Methods Mol Biol. 2018;1692:31-42
pubmed: 28986884
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Nat Rev Cancer. 2004 Jul;4(7):528-39
pubmed: 15229478
Acc Chem Res. 2019 Jun 18;52(6):1531-1542
pubmed: 31082188
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Nat Rev Cancer. 2005 Nov;5(11):899-904
pubmed: 16327766
ACS Nano. 2018 Jun 26;12(6):5834-5847
pubmed: 29750504
Front Oncol. 2019 Mar 19;9:159
pubmed: 30941310
J Med Chem. 2007 Nov 1;50(22):5509-13
pubmed: 17915851
Cancer Res. 2013 Jan 15;73(2):561-70
pubmed: 23117883
Nat Commun. 2016 Dec 19;7:13818
pubmed: 27991503
Chem Rev. 2011 Feb 9;111(2):765-89
pubmed: 20726523
Int J Cancer. 2002 May 1;99(1):130-7
pubmed: 11948504
Mol Pharm. 2017 Sep 5;14(9):3105-3113
pubmed: 28806513
Cancer Metastasis Rev. 2019 Jun;38(1-2):259-295
pubmed: 31030373
Nat Rev Cancer. 2012 Jan 12;12(2):133-43
pubmed: 22237392
Front Immunol. 2015 May 06;6:201
pubmed: 25999946
Cancer Res. 2006 Jul 1;66(13):6732-40
pubmed: 16818648
Biomaterials. 2013 Apr;34(13):3489-502
pubmed: 23410679
J Am Chem Soc. 2019 Aug 14;141(32):12475-12480
pubmed: 31353894
J Biomed Nanotechnol. 2014 Sep;10(9):1751-83
pubmed: 25992440
Mol Cancer. 2016 Nov 8;15(1):69
pubmed: 27825361
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Nanomedicine (Lond). 2012 May;7(5):663-77
pubmed: 22630150
Molecules. 2017 Dec 25;23(1):
pubmed: 29295564
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Drug Metab Pers Ther. 2019 Feb 1;34(1):
pubmed: 30707682
Biochem Pharmacol. 2012 Jan 1;83(1):16-26
pubmed: 21964343
ACS Appl Mater Interfaces. 2015 Feb 18;7(6):3618-25
pubmed: 25625307
Nanoscale. 2013 Jul 7;5(13):6106-16
pubmed: 23728482
Front Cell Dev Biol. 2017 Mar 07;5:18
pubmed: 28326306
Bioconjug Chem. 2011 Oct 19;22(10):1946-53
pubmed: 21863904
J Med Chem. 2006 Mar 23;49(6):1910-5
pubmed: 16539377
Int J Nanomedicine. 2019 Mar 26;14:2069-2089
pubmed: 30988609
Mol Pharm. 2013 Nov 4;10(11):4229-41
pubmed: 24066900
Obstet Gynecol. 2016 Jun;127(6):1003-11
pubmed: 27159753
Sci Rep. 2018 Feb 15;8(1):3078
pubmed: 29449583
Biomaterials. 2005 Dec;26(36):7628-35
pubmed: 16023201
Int J Cancer. 2004 Oct 20;112(1):121-9
pubmed: 15305383